So Yoon Ahn1, Yun Sil Chang2, Dong Kyung Sung1, Hye Soo Yoo1, Se In Sung1, Soo Jin Choi3, Won Soon Park4. 1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. 3. Biomedical Research Institute, MEDIPOST Co., Ltd., Seoul, Korea. 4. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: wonspark@skku.edu.
Abstract
BACKGROUND AIMS: The aim of this study was to determine the optimal cell type for transplantation to protect against neonatal hyperoxic lung injury. To this end, the in vitro and in vivo therapeutic efficacies and paracrine potencies of human umbilical cord blood-derived mesenchymal stromal cells (HUMs), human adipose tissue-derived mesenchymal stromal cells (HAMs) and human umbilical cord blood mononuclear cells (HMNs) were compared. METHODS: Hyperoxic injury was induced in vitro in A549 cells by challenge with H2O2. Alternatively, hyperoxic injury was induced in newborn Sprague-Dawley rats in vivo by exposure to hyperoxia (90% oxygen) for 14 days. HUMs, HAMs or HMNs (5 × 10(5) cells) were given intratracheally at postnatal day 5. RESULTS: Hyperoxia-induced increases in in vitro cell death and in vivo impaired alveolarization were significantly attenuated in both the HUM and HAM groups but not in the HMN group. Hyperoxia impaired angiogenesis, increased the cell death and pulmonary macrophages and elevated inflammatory cytokine levels. These effects were significantly decreased in the HUM group but not in the HAM or HMN groups. The levels of human vascular endothelial growth factor and hepatocyte growth factor produced by donor cells were highest in HUM group, followed by HAM group and then HMN group. CONCLUSIONS: HUMs exhibited the best therapeutic efficacy and paracrine potency than HAMs or HMNs in protecting against neonatal hyperoxic lung injury. These cell type-dependent variations in therapeutic efficacy might be associated or mediated with the paracrine potency of the transplanted donor cells.
BACKGROUND AIMS: The aim of this study was to determine the optimal cell type for transplantation to protect against neonatal hyperoxic lung injury. To this end, the in vitro and in vivo therapeutic efficacies and paracrine potencies of human umbilical cord blood-derived mesenchymal stromal cells (HUMs), human adipose tissue-derived mesenchymal stromal cells (HAMs) and human umbilical cord blood mononuclear cells (HMNs) were compared. METHODS:Hyperoxic injury was induced in vitro in A549 cells by challenge with H2O2. Alternatively, hyperoxic injury was induced in newborn Sprague-Dawley rats in vivo by exposure to hyperoxia (90% oxygen) for 14 days. HUMs, HAMs or HMNs (5 × 10(5) cells) were given intratracheally at postnatal day 5. RESULTS:Hyperoxia-induced increases in in vitro cell death and in vivo impaired alveolarization were significantly attenuated in both the HUM and HAM groups but not in the HMN group. Hyperoxia impaired angiogenesis, increased the cell death and pulmonary macrophages and elevated inflammatory cytokine levels. These effects were significantly decreased in the HUM group but not in the HAM or HMN groups. The levels of humanvascular endothelial growth factor and hepatocyte growth factor produced by donor cells were highest in HUM group, followed by HAM group and then HMN group. CONCLUSIONS: HUMs exhibited the best therapeutic efficacy and paracrine potency than HAMs or HMNs in protecting against neonatal hyperoxic lung injury. These cell type-dependent variations in therapeutic efficacy might be associated or mediated with the paracrine potency of the transplanted donor cells.
Authors: So Yoon Ahn; Yun Sil Chang; Dong Kyung Sung; Se In Sung; Jee-Yin Ahn; Won Soon Park Journal: Cell Transplant Date: 2016-08-16 Impact factor: 4.064
Authors: Joseph B Moore; Xian-Liang Tang; John Zhao; Annalara G Fischer; Wen-Jian Wu; Shizuka Uchida; Anna M Gumpert; Heather Stowers; Marcin Wysoczynski; Roberto Bolli Journal: Basic Res Cardiol Date: 2018-11-16 Impact factor: 17.165
Authors: Dong Kyung Sung; Yun Sil Chang; Se In Sung; Hye Soo Yoo; So Yoon Ahn; Won Soon Park Journal: Cell Microbiol Date: 2015-10-27 Impact factor: 3.715
Authors: So Yoon Ahn; Yun Sil Chang; Myung Hee Lee; Se In Sung; Byong Sop Lee; Ki Soo Kim; Ai-Rhan Kim; Won Soon Park Journal: Stem Cells Transl Med Date: 2021-04-20 Impact factor: 6.940
Authors: Dong Kyung Sung; Yun Sil Chang; So Yoon Ahn; Se In Sung; Hye Soo Yoo; Soo Jin Choi; Soo Yoon Kim; Won Soon Park Journal: PLoS One Date: 2015-08-25 Impact factor: 3.240